...market cap of $50.6 billion.The road aheadSeveral amyloid therapies remain in development for Alzheimer’s, including BAN2401...

...that have shown an effect on cognition in early trials, such as Alzheon’s ALZ-801 or BAN2401...
...Ltd. (Tokyo:5483), the greatest benefit was seen in APOE4 patients (see “ Data Raise Possibility BAN2401...
...is an oral small molecule prodrug of tramiprosate, an inhibitor of amyloid formation and neurotoxicity; BAN2401...

...from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401...
...Biogen did not respond in time for comment. The companies partnered to develop elenbecestat and BAN2401...
...BAN2401 for early AD a day later (see “Aggregating Hypotheses” ; “Biogen’s Lead Balloon” ). BAN2401...

...elenbecestat in early 2020: one as monotherapy, and the other in combination with anti-amyloid mAb BAN2401...
...Targets: APOE - Apolipoprotein E; BACE1 - Beta-site APP-cleaving enzyme 1 Elizabeth S. Eaton, Staff Writer ACI-24 BAN2401 CNP520 elenbecestat...

...the Japanese company and the Alzheimer's Clinical Trials Consortium (ACTC) have selected anti-β amyloid therapy BAN2401...
...comprising BAN2401 and Eisai’s β-site APP-cleaving enzyme (BACE) inhibitor elenbecestat. Eisai, which has rights to BAN2401...
...under a 2007 deal, is also conducting the Phase III Clarity AD/Study 301 trial of BAN2401...

...that conclusion, Eisai announced on March 22 it would start a Phase III trial of BAN2401...
...symptomatic patients. He thinks the target should be abandoned in the setting “only if” Eisai’s BAN2401...
...Medical School and co-director of the Center for Neurologic Diseases at Brigham and Women’s Hospital. BAN2401’s...

...Biogen is analyzing data from ENGAGE, EMERGE and a Phase II study of β-amyloid inhibitor BAN2401...
...the development" of its remaining β-amyloid programs: elenbecestat, a beta-site APP-cleaving enzyme (BACE) inhibitor, and BAN2401...
...was down $5.81 to $224.40 Wednesday. Consensus figures provided by FactSet. Elizabeth S. Eaton, Staff Writer aducanumab (BIIB037) BAN2401 elenbecestat...

...of high-risk patients across the treatment and placebo arms for another anti-β amyloid Alzheimer's candidate, BAN2401...

...hypothesis, announcing March 22 that it would start the Phase III Clarity AD trial of BAN2401...
...trial, but Eisai is leading development of the compound under their 2014 deal to co-develop BAN2401...
...the stock’s March 2015 high. Eisai announced Friday it would start Phase III testing of BAN2401...